Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic‐Phase Chronic Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03625388
Recruitment Status : Recruiting
First Posted : August 10, 2018
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Hikma Pharmaceuticals LLC

Brief Summary:
The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic myeloid leukemia (CML)

Condition or disease Intervention/treatment Phase
Chronic Myelogenous Leukemia Drug: Dasatinib Phase 2

Detailed Description:
A multicenter, prospective, open-label, randomized Phase II study to compare efficacy by measuring rates of major molecular response (MMR) at 12 months in patients with Ph+ chronic phase (CP) chronic myeloid leukemia (CML) randomized to receive either dasatinib 50 mg QD or dasatinib 100 mg QD. Approximately 100 patients are expected to be randomized. The duration of patient participation will be 18 months

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Eligible patients will be randomized to receive either dasatinib 50 mg or dasatinib 100 mg orally once daily for the duration of the study which is 18 months.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
Actual Study Start Date : November 5, 2018
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021


Arm Intervention/treatment
Dasatinib 50 mg
Dasatinib 50 mg orally once daily
Drug: Dasatinib
Film coated tablet contains dasatinib monohydrate
Other Name: Elpida®

Dasatinib 100 mg
Dasatinib 100 mg orally once daily
Drug: Dasatinib
Film coated tablet contains dasatinib monohydrate
Other Name: Elpida®




Primary Outcome Measures :
  1. Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test [ Time Frame: 12 months ]
    Major molecular response (MMR) is defined as BCR-ABL1 ≤ 0.1%


Secondary Outcome Measures :
  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) to dasatinib [ Time Frame: 18 months ]
    Evaluation of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests according to laboratory reference ranges

  2. Transformation free survival (TFS) in eligible patients randomized to dasatinib 50 mg or dasatinib 100 mg treatment arms [ Time Frame: 18 months ]
    Transformation free survival was measured from the start of therapy to the date of transformation to accelerated or blastic phases while on therapy or to the date of last follow-up.

  3. Event free survival (EFS) [ Time Frame: 18 months ]
    EFS is measured from the start of treatment to the date of any of the following events : loss of CHR, loss of CCyR or MCyR, dose escalation, discontinuation of therapy for toxicity or lack of efficacy, progression to AP or BP, or death from any cause at any time

  4. Blastic phase (BP) transformation [ Time Frame: 18 months ]
    BP is defined as the presence of 30% blasts or more in the peripheral blood or bone marrow

  5. Overall survival [ Time Frame: 18 months ]
    Overall survival time is defined as the time from date of randomization until the date of death from any cause at any time or date of last follow up

  6. Proportion of patients with Complete cytogenetic response (CCyR) at 12 months [ Time Frame: 12 months ]
    defined as 0% Ph+ metaphases, or FISH ≤2%, or BCR-ABL transcripts (IS) ≤1%

  7. Proportion of patients with MR 4.5 at 18 months [ Time Frame: 18 months ]
    (BCR-ABL transcripts ≤ 0.0032%)

  8. Health‐Related Quality of Life (HRQoL): EORTC QOLCML24 [ Time Frame: 18 months ]
    Mean change in Health‐Related Quality of Life (HRQoL) utilizing EORTC QOLCML24 questionnaire throughout treatment visits

  9. Frequency of not taking the medications as prescribed [ Time Frame: 18 months ]
    Evaluated by identifying the frequency of not taking the medications as prescribed and the reasons. The decision on non‐compliance is based on the treating physician's judgment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Diagnosis of Ph+ or BCR-ABL positive CML in early CP (i.e. time from diagnosis <12 months). Except for hydroxyurea and/or 1-2 doses of cytarabine (up to 6g/m2 total), patients must have received no or minimal prior therapy, defined as 30 days of prior approved tyrosine kinase inhibitor (TKI).
  3. Clonal evolution defined as the presence of additional chromosomal abnormalities other than the Ph-chromosome has been historically included as a criterion of accelerated phase (AP). However, patients with clonal evolution as the only criterion of AP have a significantly better prognosis, and when present at diagnosis may not impact the prognosis at all. Thus, patients with clonal evolution and no other criteria for AP will be eligible for this study.
  4. ECOG performance of 0-2.
  5. Adequate end organ function defined as the following: total bilirubin <1.5x ULN (unless secondary to Gilbert's disease, in which case it should be <2.5x ULN), SGPT <2.5x ULN, creatinine <1.5x ULN.
  6. Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital

Exclusion Criteria:

  1. NYHA cardiac class 3-4 heart disease
  2. Cardiac symptoms - Patients meeting the following criteria are not eligible unless cleared by a cardiologist:

    1. Uncontrolled angina within 3 months
    2. Diagnosed or suspected congenital long QT syndrome
    3. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    4. Prolonged QTc interval on pre-entry electrocardiogram (>460 msec)
  3. History of significant bleeding disorder unrelated to cancer including:

    1. Diagnosed congenital bleeding disorders (e.g. Von Willebrand's disease)
    2. Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies)
    3. Isolated thrombocytopenia without recurrent bleeding episodes shall be considered eligible for study entry
  4. Patients with active uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders
  5. Women of pregnancy potential must practice an effective method of birth control, unless otherwise instructed, during the course of the study in a manner such that risk of failure is minimized

    1. Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy
    2. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
    3. Women must continue birth control for the duration of the study and at least 3 months after the last dose of study drug
  6. Pregnant or breast-feeding women are excluded

    a. All WOCBP must have a negative pregnancy test prior to first receiving the study drug. If the pregnancy test is positive, the patient must not receive the study drug and must not be enrolled in the study.

  7. Patients in late chronic phase (i.e. time from diagnosis to treatment >12 months), accelerated phase (except as noted in inclusion criteria 2) or blast phase are excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03625388


Contacts
Layout table for location contacts
Contact: Hikma Pharmaceuticals 009625805430 ext 11663 medical-information@hikma.com

Locations
Layout table for location information
Jordan
King Hussein Cancer Center (KHCC) Recruiting
Amman, Jordan, 11941
Jordan University Hospital (JUH) Recruiting
Amman, Jordan, 11942
Lebanon
American University of Beirut Medical Center (AUBMC) Not yet recruiting
Beirut, Lebanon
Saudi Arabia
The King Faisal Specialist Hospital and Research Centre (KFSH&RC) Not yet recruiting
Riyadh, Saudi Arabia
Tunisia
Aziza Othmana Hospital Not yet recruiting
Tunis, Tunisia, 1006
Sponsors and Collaborators
Hikma Pharmaceuticals LLC

Layout table for additonal information
Responsible Party: Hikma Pharmaceuticals LLC
ClinicalTrials.gov Identifier: NCT03625388     History of Changes
Other Study ID Numbers: LPI-JOR-LEB-KSA-TUN-2017-01
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hikma Pharmaceuticals LLC:
Leukemia, Myeloid, Philadelphia Positive
Dasatinib
Generic Dasatinib
Dasatinib 50 mg once daily
Early chronic phase chronic myeloid leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Dasatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action